Shionogi Acquires 85 Percent Of Sciele
This article was originally published in PharmAsia News
Executive Summary
Shionogi says its tender offer for control of U.S.-based Sciele Pharma has been met and it now has more than 85 percent of the shares. Shionogi extended its deadline for the remaining shareholders to sell their stock to Shionogi. The Japanese drug maker expects to pay about $1.5 billion for the medium-size Sciele. (Click here for more - a subscription may be required